Suggested remit: To appraise the clinical and cost effectiveness of omaveloxolone within its marketing authorisation for treating Friedreich’s ataxia in people 16 years and over.
 
Status In progress
Technology type Medicine
Decision Awaiting decision
Process STA Standard
ID number 6423

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6423 12 July 2024 - 09 August 2024

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
12 July 2024 In progress. Scoping commenced.
24 June 2024 This appraisal has been referred to NICE and is due to begin late October 2024.
12 October 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
12 October 2023 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual